Lyra Therapeutics LYRA

$ 0.19 1.81%

Quarterly report 2024-Q3
added 11-12-2024

Lyra Therapeutics Balance Sheet 2011-2024 | LYRA

Annual Balance Sheet Lyra Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	4.53 M	-30.3 M	-44.3 M	-72.2 M	-6.48 M	-23.9 M	-	-	-	-	-	-	-
Long Term Debt	21.4 M	667 K	379 K	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	5.43 M	1.55 M	1.07 M	985 K	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	1.45 M	2.43 M	130 M	-	-	-	-	-	-	-
Total Current Liabilities	19.6 M	14.5 M	18.2 M	4.88 M	-	-	-	-	-	-	-	-	-
Total Liabilities	53.2 M	29.2 M	20.6 M	6.34 M	7.64 M	132 M	-	-	-	-	-	-	-
Deferred Revenue	1.66 M	1.28 M	9.79 M	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-311 M	-249 M	-193 M	-150 M	-128 M	-111 M	-	-	-	-	-	-	-
Total Assets	143 M	110 M	54.9 M	80.8 M	15 M	25.4 M	-	-	-	-	-	-	-
Cash and Cash Equivalents	22.4 M	32.6 M	45.7 M	74.6 M	-	-	-	-	-	-	-	-	-
Book Value	89.4 M	80.8 M	34.3 M	74.5 M	7.33 M	-107 M	-	-	-	-	-	-	-
Total Shareholders Equity	89.4 M	80.8 M	34.3 M	74.5 M	-123 M	-	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Lyra Therapeutics

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	31.3 M	32.5 M	33.4 M	21.4 M	4.89 M	-	191 K	667 K	3 K	3 K	99 K	379 K	656 K	929 K	1.2 M	1.45 M	1.45 M	1.45 M	1.45 M	2.43 M	2.43 M	2.43 M	2.43 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	58.1 M	63.6 M	64 M	53.2 M	36.3 M	27.1 M	27.8 M	29.2 M	26.2 M	19 M	19.2 M	20.6 M	20.6 M	18.8 M	5.37 M	6.34 M	6.34 M	6.34 M	6.34 M	7.64 M	7.64 M	7.64 M	7.64 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	607 K	814 K	1.32 M	1.66 M	1.73 M	1.5 M	1.51 M	1.28 M	2.73 M	1.81 M	10.1 M	9.79 M	9.84 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-394 M	-382 M	-334 M	-311 M	-296 M	-281 M	-265 M	-249 M	-234 M	-215 M	-200 M	-193 M	-180 M	-169 M	-158 M	-150 M	-150 M	-150 M	-150 M	-128 M	-128 M	-128 M	-128 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	78.8 M	94.6 M	142 M	143 M	121 M	126 M	93.9 M	110 M	119 M	130 M	47.3 M	54.9 M	67.8 M	76.3 M	72.9 M	80.8 M	80.8 M	80.8 M	80.8 M	15 M	15 M	15 M	15 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	23.8 M	31.9 M	15.8 M	22.4 M	24.8 M	54.4 M	22 M	32.6 M	110 M	121 M	33.8 M	45.7 M	58.1 M	69 M	66.1 M	74.6 M	74.6 M	74.6 M	74.6 M	9.81 M	9.81 M	9.81 M	9.81 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	20.6 M	31 M	77.5 M	89.4 M	84.2 M	98.6 M	66.1 M	80.8 M	93.2 M	111 M	28.2 M	34.3 M	47.2 M	57.5 M	67.6 M	74.5 M	74.5 M	74.5 M	74.5 M	7.33 M	7.33 M	7.33 M	7.33 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	20.6 M	31 M	77.5 M	89.4 M	84.2 M	98.6 M	66.1 M	80.8 M	93.2 M	106 M	23.3 M	34.3 M	47.2 M	57.5 M	67.6 M	74.5 M	74.5 M	74.5 M	74.5 M	-123 M	-123 M	-123 M	-123 M	-107 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency